Literature DB >> 22350537

Disruption of programmed masticatory movements in unilateral MPTP-treated monkeys as a model of jaw movement abnormality in Parkinson's disease.

Kazunori Adachi1, Masayuki Kobayashi, Toshiyuki Kawasaki, Chihiro Yokoyama, John L Waddington, Hiroshi Sakagami, Hirotaka Onoe, Noriaki Koshikawa.   

Abstract

While motor disturbance in Parkinson's disease can affect innate, programmed processes, such as masticatory mandibular movements, the pathophysiology of such abnormalities remains unclear. This study applies digital analysis by high-speed video signal processing that tracks three dots placed around the mouth for recording masticatory movements in unilateral 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys. The system analyzes displacement, velocity and cycle duration of the topography of mandibular movement during mastication of sweet potato slices. In monkeys receiving MPTP into the right carotid artery (n = 3), positron emission tomography indicated significant reduction in the binding of (E)-N-(3-iodoprop-2-enyl)-2β-carbo[(11)C]methoxy-3β-(4-methylphenyl)nortropane ([(11)C]PE2I) to the dopamine transporter in the right caudate, putamen, nucleus accumbens and substantia nigra relative to the contralateral hemisphere. These monkeys showed hypokinesia of the left forelimbs and hindlimbs. During mastication, MPTP-treated monkeys chewed preferentially on the left side, while untreated monkeys (n = 3) showed no preference for chewing side. The amplitude of vertical opening and closing movements was reduced in MPTP-treated monkeys, with a slight but significant increase in the lateral component of mandibular movements. The velocity of all phases of horizontal mandibular movements was reduced. In consequence, duration of the occlusal phase was increased, while duration of the closing phase was decreased in MPTP-treated monkeys. These findings indicate that during masticatory movements MPTP-treated monkeys chew preferentially on the side contralateral to loss of dopamine neurons, with reduced amplitude and velocity of mandibular movements. High-speed digital movement analysis is able to define and quantify abnormalities of orofacial movement topography as a sign of parkinsonism.

Entities:  

Mesh:

Year:  2012        PMID: 22350537     DOI: 10.1007/s00702-012-0768-0

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  35 in total

1.  Multiple output channels in the basal ganglia.

Authors:  J E Hoover; P L Strick
Journal:  Science       Date:  1993-02-05       Impact factor: 47.728

Review 2.  Nigral and extranigral pathology in Parkinson's disease.

Authors:  H Braak; E Braak; D Yilmazer; C Schultz; R A de Vos; E N Jansen
Journal:  J Neural Transm Suppl       Date:  1995

3.  [123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys.

Authors:  J Booij; G Andringa; L J Rijks; R J Vermeulen; K De Bruin; G J Boer; A G Janssen; E A Van Royen
Journal:  Synapse       Date:  1997-11       Impact factor: 2.562

4.  Effects of pontomedullary reticular formation stimulation on the neuronal networks responsible for rhythmical jaw movements in the guinea pig.

Authors:  S H Chandler; L J Goldberg
Journal:  J Neurophysiol       Date:  1988-03       Impact factor: 2.714

5.  Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients.

Authors:  Aristide Merola; Maurizio Zibetti; Serena Angrisano; Laura Rizzi; Valeria Ricchi; Carlo A Artusi; Michele Lanotte; Mario G Rizzone; Leonardo Lopiano
Journal:  Brain       Date:  2011-06-11       Impact factor: 13.501

6.  Monosynaptic innervation of trigeminal motor neurones involved in mastication by neurones of the parvicellular reticular formation.

Authors:  D Mogoseanu; A D Smith; J P Bolam
Journal:  J Comp Neurol       Date:  1993-10-01       Impact factor: 3.215

7.  The predictive validity of the drug-naive bilaterally MPTP-treated monkey as a model of Parkinson's disease: effects of L-DOPA and the D1 agonist SKF 82958.

Authors:  G Andringa; L Lubbers; B Drukarch; J C Stoof; A R Cools
Journal:  Behav Pharmacol       Date:  1999-03       Impact factor: 2.293

8.  Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.

Authors:  M Lundblad; M Andersson; C Winkler; D Kirik; N Wierup; M Angela Cenci
Journal:  Eur J Neurosci       Date:  2002-01       Impact factor: 3.386

9.  Dopaminergic and cholinergic stimulation of the ventrolateral striatum elicit rat jaw movements that are funnelled via distinct efferents.

Authors:  Kazunori Adachi; Megumi Hasegawa; Satoshi Fujita; Michiko Sato; Yasuhiro Miwa; Hiroko Ikeda; Noriaki Koshikawa; Alexander R Cools
Journal:  Eur J Pharmacol       Date:  2002-05-03       Impact factor: 4.432

10.  The relationship between parkinsonian rigidity and hypokinesia in the orofacial system: a quantitative analysis.

Authors:  C J Hunker; J H Abbs; S M Barlow
Journal:  Neurology       Date:  1982-07       Impact factor: 9.910

View more
  2 in total

Review 1.  The use of nonhuman primate models to understand processes in Parkinson's disease.

Authors:  Javier Blesa; Inés Trigo-Damas; Natalia López-González Del Rey; José A Obeso
Journal:  J Neural Transm (Vienna)       Date:  2017-03-29       Impact factor: 3.575

2.  Parkinson's disease impairs masticatory function.

Authors:  Giselle Rodrigues Ribeiro; Camila Heitor Campos; Renata Cunha Matheus Rodrigues Garcia
Journal:  Clin Oral Investig       Date:  2016-06-13       Impact factor: 3.573

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.